TXMD - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen. Thank you for joining us for the TherapeuticsMD Fourth Quarter 2020 Financial Results Conference Call. [Operator Instructions] I would now like to turn the call over to TherapeuticsMD's Vice President of Investor Relations, Nichol Ochsner. Nichol.

Nichol Ochsner

Thank you. everyone. morning, Good joining results for discuss fourth our Thank business today update. financial and quarter you to This issued financial results. morning, fourth our TherapeuticsMD a press announcing release, quarter press website, the & The section. available the Media in Investors company's is release therapeuticsmd.com, on Executive Mitchell On Chief Robert Krassan. Commercial Dawn Financial are Strategy Chief Chief Finizio; Halkuff D'Arecca; Officer, and today's James and TherapeuticsMD call Officer, from Chief Officer, Performance Officer; remind this statements. like to everyone conference may would statements during that I made forward-looking call contain certain expectations, current statements and can forward-looking statements upon Such results these based assurances no in the will there that are be realized. contemplated be may statements press with of which number materially and and results Actual some identified the SEC. are differ quarterly from filed release due to of reports risks, and such our a our in annual, factors other information are to company statements statements and the to on no change. as circumstances forward-looking today, based assumes TherapeuticsMD obligation update available These and recording in audio will online conference today's available the An website. be of & replay also webcast section company's Investors call the for Media

For webcast, this who the CEO, archived XX, held to recorded and turn call replay was XXXX. over may to March the Finizio. the benefit TherapeuticsMD be that, call or I'll listening Rob of With those

Robert Finizio

of strengthen We we record sheet the capital year total remainder our as commercial We've our net product focus revenue strengthening with for will our our executed the today's we quarter for updated commercial and delivered multiple equity fourth successfully priorities term a company. full on We plans. On operating morning. capital net structure agility Good demonstrating a execution and and performance. a operational quarter lowered strong through call, our on financial made our discipline. maintaining our debt. on Progress raises review our and strong our while and year strict revenue covenants reduce balance loan of expenses,

mention James recently call divesture over that James. Before I'd will also over I the forward still call to now we've turn moving multiple progress, to I like achieved. on the process as the is parties. to transformative you the the give turn interested detail to vitaCare

James D'Arecca -

Rob. Thanks

our Slide reviewing our would to Before elaborate balance our X. Turn quarter fourth results, to on like discuss updates lender. sheet I with and financial

the last balance net over $XXX which recently $XXX completed after We over to earlier million brought balance have in by proceeds sheet our raising November, strengthened offering this month since cash million. the

which in vitaCare down strong will gain the for enabled has covenants terms of interest $XX our March. us our prescription key Paying products. work to life debt future on the us position favorable debt Our move to their believe and with remaining loan, expense lender forward reduce will debt also stage pay our of services, divest commercialization our reflect we remaining as at can the terms and allows on down more facilitate consent to cash the advancing the the reduce we end future by of refinancing of we that of it the of million

and BIJUVA. mentioned, lender with for aggregate IMVEXXY, our covenants our Rob update As revenue agreed ANNOVERA, have to we

$X now is XXXX third revenue $XX $XX now million, $XX and first is $XX.X time quarter quarter million increases Our second first million. covenant quarter quarter fourth that is After million, quarter million, is per million is quarter. $XX

covenant And poised our avoid further de is headroom net efforts. along leveraging our commercialization current pandemic COVID-XX are have expectations solely now sufficiently given revenue set below state are While our the been of and guidance, provide sufficient updated our to to focus we believe revenue believe at levels revenue in formal minimum covenants our these we transformational. on We adjustment. with executing that

of our the from fourth quarter. metrics results on move financial a key Let's to review and

significantly our fourth covenant. quarter fourth This quarters quarter. ANNOVERA Turning at increase revenue with unit. revenue which in $XXXX This satisfied a net increase per per XX% the from in prior increase average product in overall was net increased revenue the most $XX.X our quarter by unit the was net with to the remaining from revenue driven line for X, third million, net Slide XX% to revenue

Additionally, as see The revenue per also can on BIJUVA, the and and for chart, for XX% IMVEXXY unit you and $XX net to IMVEXXY quarter a $XX XX%, the revenue to net increased respectively, compared BIJUVA. increased on basis. by previous average

levels our for products three As wholesale weeks. of yearend, normal five to of were inventory levels within

Moving some statement key financial on to review let's Slide X, items.

the quarter. product X percentage gross third in decreased Our margin of the fourth points quarter XX% over

Our announced are costs our initiatives our strict for billion allowed to second discipline to goods was reduce of the $XXX,XXX for and of by to in us expenses which IMVEXXY attributable previously pandemic. focused were The savings and each operating $XXX,XXX goal $XX ANNOVERA adversely of OpEx fourth BIJUVA, affected gross write finished offs results half quarter of cost margin on XXXX. achieve inventory for of and and the

million and items the non-cash Cash the decreased to enhance for performance fourth quarter. retention $XX.X across a $X by Excluding million Net $XX third for activities million the of operating from $X.X to incentive employee organization. in used million quarter

investments plan we can our supply initiatives. related capabilities marketing grows, this enhance and year expect revenue maintain base efficient digital we While leveraged to to that an chain, to be cost commercial as to strengthen make improve

to Dawn in of $XXX minimum to $XX what state in the raising the debt. million of and COVID-XX turn second since committing by OpEx covenants our quarters sheet we have payer progress growth continued now Slide balance $XX with accomplishments short current XXXX, XXXX. successfully pleased to cash I TXMD. and Revised down operational to believe our pay average time, for million expect financial are our believe this given reduced Over well cash plans. poised I'd of million our strengthen and to for in to $XX half conclusion, on two previous per OpEx our our have expenses the are execute meeting commercial Turn commercial levels operating we in In to we like by pandemic. cash we our We joined revenue X. discuss million goal been cash over million the $XX quarter and over XXXX. investments, and call in positioned I these to plans to With burn the

Dawn Halkuff

a of start James. will and payer this Thanks, quick then status quarter. performance product with in overview our portfolio I review across the seen

Let's start XX. on access updates Slide with payer and

XX% unrestricted moves to We in have product maintained BIJUVA IMVEXXY coverage XX%. the and improvement all major to portfolio; payers across ANNOVERA to XX%, commercial

XX. by patients ANNOVERA, filled to move performance hand on side. total Let's Quarterly Slide left on the prescriptions is

quarter. continued prescriptions quarter. for quarter, XXXX at grow XX% and XXXX per Net unit at total the approximately you to remained in net see, total XX% revenue prescriptions ANNOVERA with quarter fourth increasing the third As grew can coming strong revenue over over

To in for with to I'll a Turning level the understanding of at base prescribers. bit provide our key prescriber let's XX. more long prescriber look start progress, leading Growth indicators Slide ANNOVERA a consumer metrics. and for across is trajectory. term

this of by seen prescription been growing growth But writing, the blue and growth on number As number are limited to prescriber writers. the the navigating prescribing by COVID. and line during continue and we've in see green as the shown as faster than the mentioned, total has of prescribers total we indicated bars depth access total of

Whitney our made we of campaign activities December, decisions consumer. The column leaned by we placement X.X Cummings. into been Just billion in has the launched outlets, consumer XX% The interest spokesperson significant impressions say XX, on and called, the significant with multiple program the to it media Vagina. left. generated the celebrity In shown in birth Turning Slide consumer the given that as have portion are of control

show platforms, seeing our impact early website the multiple Traffic words, the to we a to XXXX. on is all from above growing encouraging. In to of the tech day. results and the prescriptions rises working, are leading to advertising the is over believe intend XX,XXX with through rates trajectory website consumer it And request to in increase the our advertising strategy XX%. addition, other In industry Click or in visits after norms. live will ANNOVERA antibiotic website significantly indicators

to XX. Turning Slide

how this attract interest As interest fill affordably the to figured to is create we in consumer and consumer ANNOVERA, you see, improve next step we where converting can out need to have conversion believe track to progression we the on right conversion month and from is to we process the the typical improve learning prescriptions. were launch. for next over quarters. a And interest This

cycles the of to about XX, we'd talk woman XX value and patient Turning earned because of is each dispensed. is the is for value year when full revenue on like amount ANNOVERA. Each of TXMD, significant a to Slide now creates revenue a product for therapy

the continues of can value women with you grow cumulative by therapy. see almost the to As XX,XXX slide, on ANNOVERA

compounded strong we XX% addition, opportunity. will believe approximately our In retail rate a strong future revenue of create

Slide XX. on opportunity let's IUD not in they a not it are or for implant marketplace, is half Close an in well want new to Implant the because understood future everyone. offer women fills move create larger we undergo for the and or to void ANNOVERA control. believe birth of procedure. reject do IUD Now the of a that It to can ANNOVERA segment the

GYN procedures to provide acting The need option of long over their to addition, In therefore to Slide patient. ANNOVERA. A a Turn don't half XX. both of trend entry cancer is these solution free home conduct issues of this marketplace example removes OB One growing and procedure the a in at free barriers for solution reluctant to is It successful a undergo for many screening. to procedure. people colorectal of the solutions. Cologuard, in procedure is home at are

expand screened birth the but way. previously for the reluctant want of ANNOVERA a the can barrier untested. that entry with to segment Cologuard, moving have those the undergo We long category in million product, to procedure. them of acting a people long acting the believe fact, same been for are In We're control X half

Slide Turning to XX.

Let's look continuum. at contraceptive the

of market control options long left of screening. left long a void procedure on acting a short And daily as hand benefit new side a require procedure. acting but declining. are require monthly create fills medical market right cancer to ANNOVERA and and options product the colorectal Cologuard provide did the free does the acting the for void believe we and that that a In are long and not that procedure are a the growing. ANNOVERA that the of birth segment of acting chart but On segment are filling

in the Turning the to new for evidence Slide data. marketplace a the is ANNOVERA segment XX. become in to In

left the the hand of chart are On segments of birth main the control. side

the here birth middle and switching to to on data from you were ANNOVERA. control prior to column women patient see vitaCare which actual Moving

the than the to same, coming is over from Moving is of right half benefits are products sets both given the they claim data data control the ANNOVERA. of from survey column, the patients benefits that from are takeaway of as NuvaRing ANNOVERA multiple are The birth form. more prescriptions prescribers main switch hand this of on where not

Slide to Moving XX.

Before ANNOVERA new and us closing annually. market financial a products in on the have million is Birth to category grounding XX minutes let's a larger opportunity prescriptions share. X% opportunity. this To with million put large spend market achieved time few women ANNOVERA, perspective, in X% over in traditionally, leading control XX

the the approximately benefits see ANNOVERA column, free can column a would in the of in in mean market And different on in annually. share [ph] of prescriptions and years. in and same XXX,XXX is level XXXX you five the middle procedure right, approximately which of As market the achieve this success the achieved share achieved Western screening at Lola seen home years. Cologuard launched X% four the it offers but

product. menopausal our review let's Now,

quarter by Slide Net NRx have XX% Total a XX. X.X% quarter. an fourth to QX. is the over quarters, side. In approximately to XXX,XXX, decline prescriptions improved the IMVEXXY which recover of pandemic. to the and begun revenue third increase on previous prescriptions result filled was over to revenue in improved X.X% $XX news, new to per Turning good attributable net decreased unit total the QX for quarterly prescriptions patients left-hand

Moving XX. to Slide

cast for To co-pay program primary from patient's goal improve expected same The increased time to program IMVEXXY to to out unit The a revenue effective but pay deductible program gross XXXX per that the impact net and Our support X, to $XX the our we high growth put cash net. IMVEXXY on pressure change. volume, $XX. change net to significant. rolled expected in cash on is gross pay positive was January is

share. life preferred XX% removed total with gained branded covers key that of January, also market currently PBM In PBM for Premarin, which has counterbalance. including We approximately competitors status a top the XX% prescription to IMVEXXY

to addition, on adherence In to higher patient partnerships distribution we are focus channels. drive retail retail continuing rates across to

short performance term Turning on to In the of is January Slide we XX, impact saw volume. in as January, on expected. changes combination based

volume that show beginning indicators recover. early However, February is for to

who In an the cost per and $XX addition, improvement revenue fill for those the co-pay we are seeing being dedication approximately rate, Today realized improvements per is revenue in net in unit. program. net use

Turning to XX. Slide

driver of is consumer a Finally, demand. growth

we testimonials that During and launched the common help to quarter, patient normal. menopause of first understand women are better symptoms

the into to life designed is second under Moving that self-care them IMVEXXY. new new and menopausal plan charge stage a consumer launch woman in take overall vaginal quarter, we with health, this to grounded campaign encourage during educate to

to Slide maintaining our touch decision BIJUVA. X.X% XX, to NRx. the with sales quickly promoted TRx with growth slight quarter I'd like to BIJUVA only in the see field, Moving to on deemphasize BIJUVA seven Even while we continue and representatives for in at

it turn increased remarks. to revenue over net improved the quarter XX% I prior for fourth the For Rob unit now net and closing $XX to revenue quarter. would per over like to

Robert Finizio

of XX. our in our not Slide our have the is covenants, both accelerate to vitaCare least, updated place transformed to adoption our revenue but sheet, IMVEXXY throughout XXXX. We've move We've let's balance moving Dawn, capital Thank now call forward frame divesture and it and ANNOVERA improved first well in Last we structure. and Thanks believe break up even the half the you the XXXX. questions. we'll even joining call anticipate to to open all And positioned a our for continue today. for we're growth very

Operator

question Our Cantor. Louise with first Instructions] comes [Operator Chen from

Louise Chen

quarter, here. the congratulations and my taking Hi, questions on for thanks

gross thing something margins thing the about So given sales year? I to that XXXX? valuation, impact in expect gave we in anticipated? Could should last about should Any and a us sale? the second as in metrics vitaCare. about And sales? some is think first much about the up is, is for of ask you think what XXXX, you how you timing then I then we on for good had of we anticipate you. OpEx. we reason an and some Is question is And see how step think do have this And thoughts have XXXX before you COVID the is update Thank then us you how

Robert Finizio

Louise its Hey, Yep. Rob.

far So something as year. expect I as vitaCare would goes, this absolutely

this very Assuming interested if divest, expect parties have and multiple are things it year. there. would definitely in nicely I we which progressing

put As first far as JPM for to out margins gross net even vaccine. very at the go, the in we around expectations time tried clear presentation including

to that the on rebates XXXX. did half was additional down is we related I with of we ANNOVERA in or up COVID back ANNOVERA. XXXX. we that's government had commercial And So what know to XXXX at related opening to and assuming year, I close were channels based obviously And government XXXX. lifts. ahead the XXXX, about going know, we here we the to stayed

there. clear we that, open color by like So out again, of to bit channel we starting Medicaid, that progression quarterly I government up for think as a if and little places put a DOD think I well. And IMVEXXY, June, then have

half headwind vaccines will new believe begin where and of back the whatever Salesforce of start take certainly there's up normal this lift be first the a hold, as and XXXX. getting far for actually to year into the in goes, getting our scale, we to the put As offices, step that a will COVID we to half new in in year is

other lot it park. revenue women the The ability department long on. with were the acting as quarters that the So lifting. next step quarter will has starting strong product, expect site on year interest, now. And over over, that we initiatives know, right And But add? learn. I'll turn with of we with working Difficulty] COVID starting is and to also two the as and next and to conversion Dawn, quarter big strong will she's moving on. cost But growth get you This to volume free the to just procedure this it a now low of we see, a day, accelerate ago, [Technical they've can that throughout XX,XXX think year. revenue that thing just you a have we're we out it marketing bring just stream at knocked ANNOVERA over coming anything

Dawn Halkuff

is add growing what's And is we're quarter. really revenue And aggregate TXMD, about environment for know, ANNOVERA value nice navigate that, of XX I'll COVID on every for nice think and you seeing, increasing of COVID that, COVID fantastic as lot maybe just Slide every is quarter-over-quarter XX%, XX% at quarter ANNOVERA, creates us of it. this in therapy what what's impact. during mean, value really what's here for the ANNOVERA value net about environment which script, this you the women and the interesting is we I amount I despite realized to the is if over that go and script we know, really could a of

product know, you we're essentially, this in monthly living data in annual So world.

means that for full year versus a a is written one time products. that for what every receive so revenue of other And the prescription is monthly of month revenue, ANNOVERA, we

you naturally acting I'll can again, focused COVID Salesforce time it's how said, So COVID helpful interest with just now, that a accessible mentioned the resonates significant we prescribers, we And in and with message of, consumers generated that's we resonates the And will Robert with to free the tell help we're an as when conversion. us normalize, the Right see ANNOVERA, part, world. reach growth XX. which long because every in us resonates, first the prescription, digitally really on you going consumers. it ANNOVERA accelerate. during it accelerate And are procedure actually COVID? Rob impact, receive the What's in terms time for and

the the allow that us lift believe so the And year restrictions accelerate. But in that's really to half of helpful. be will back access to ultimately, that we going will

Louise Chen

you. Thank

Operator

Stifel. Samimy next question with comes Our from Annabel

Annabel Samimy

question. math something simple for I simple, had thanks pretty here. guys, taking my first Hi,

you take press by If and in multiply out prescriptions net the the we've to number. price release, just we're your that it getting your not laid

update we to about about IMVEXXY? then on there next talked guess that regarding going but between variables we we be as net are much hormone stabilize Thanks. this, that any the [indiscernible] other question but COVID we for it's the you variables about when us discussion as you thinking soon ANNOVERA when the So need should and other to going I And any things price are talk there's there? think about forward plan therapy think haven't where both and are is on franchises, about? if for And the reinitiating ranges marketing FDA

Robert Finizio

about question the channels the quarter a channel, and our certain and demand On their was reporting very for sales it channel fill units. gross all difference does units in not patients net of and strong between prescriptions, illustration [ph] Symphony to up the under from the pick resulting in the the where

accomplished Second, that we all accomplished of sales net maintain growth unit this four of piece better than the That that channel. per for our in typical products. it? we inventory levels of expected into And was while maintaining approximately answer, revenue weeks

Annabel Samimy

the other I that price Are the listing in prescriptions rather? prescriptions you revenues reporting on, saying in are that that that reported. recording there revenues mean, net on you you're you're the channel

Robert Finizio

channel is are? between there's numbers our sales saying and units into the by we're Symphony the versus What reported the a what mismatch

James D'Arecca

is the get think the reported. Yes, reporting if units next you The reason our that revenue Symphony as that's that's we high so take low. you time,

Annabel Samimy

reporting the a sense percent that of low? Okay, have they're do you

Robert Finizio

to on. hard But there's hard That's one. It's at point, on wrong. I'd something working many and really that say be this guess new we're working It's so we're hate to because channels.

them. With

Annabel Samimy

you're channel? guessing in revenues do record the how if as and mean, I reporting your under to you

Robert Finizio

revenue? it You finance? turn to Let take your me over

James D'Arecca

Annabel. Hi, Yes.

on what is, think done GAAP hitting I our revenues you're basis. a upon So are

doing? that XXXX. to wholesalers. were we to that and were average the what scripts And to when numbers on multiplying I trying the patients that's So dispensed looking board that you at see take, were you like you that sell you intending think being on by Is

Annabel Samimy

in release. that's press Well, you what just I the reported mean,

can that imagined mean, be we offline. I that But, take So accurate number. would I the

applying unknown, You the net going I should we about how that? know, forward? suppose, If you I variables that how case, we there's if price about that and know, think are that's and guess should think

Robert Finizio

we So that the the x thing we scripts factory, are sell from is what wholesaler. right between and the what a difference us there's to sell that dispensed

and So there's to ebbs buying so always flows patterns and be forth. wholesale going and

will framework just doing one match but never an in they know, terms overall So for exactly you it. of up, of one

You go know, kind that you if that and it way us, way. assume model that about to for over I time of doing the you wanted that's you'd think, normalizes think I

Annabel Samimy

maybe doing any discussions to question then move well, in next we of FDA with terms progress their Okay, you're NASEM and there with regarding the can and BIJUVA? [ph], compounding on what just

Robert Finizio

point, it can NASEM or of FDA is tailwind goal that. does to breakeven we'll that. the our 'XX, we COVID track half know, you're or BIJUVA. Also, so get EBITDA at right, first lifts certainly can with for on headwinds to you Yes, moves on overcast then what top of reevaluate doing we're create as And see the And that forward.

flips So over. how each you seven card have and we and see moving upwards. a great it's it's product. behind we And people got only it certainly, to But see, wait

a and So us there's a shareholder market for resources there. matter definitely goals. of It's

going So we'll get it though.

Annabel Samimy

right. Thank you. Great. All

Operator

H.C. next Douglas Our Instructions] Wainwright. comes Tsao from [Operator question with

Douglas Tsao

just the Thanks on the questions for morning. balance sheet. good taking Hi,

know, an divest are for you. thoughts vitaCare able more like Will business. a paying know what and of like you Just to account more use your proceeds? of if you Is to you? the curious debt? terms if when Or, in it's down Thank plan be you an on going the option you're that

Robert Finizio

the thanks Yes, question. for

to keep or set future, whose allow, we further conditions So, as to had was down. venture really debt or in create us cost lower long structure debt current do package covenant down I our that debt allow pay here just first The not before COVID. pursue when we started, whether did, market pay optionality we extensive the

the like that's have. think But I analysis to that subject bunch optionality a we we'd that of here. different

and business you which which our allows Additionally, in plan of maximize focus, consent vitaCare its up return an to that improves the to brought interest. with we value of that vitaCare,

up think a balance set position, that to like really in I here better we now have and we're much So I sheet wise.

James D'Arecca

more think don't down we'll be the to answer expectation; your I current in Doug, to debt future near question. any the paying

Douglas Tsao

then And some for were terms nets, IMVEXXY. just improvement, obviously the gross Okay. especially in seeing of

quarter You just see and know, you've utilization first little I resets, get the deductible sometimes you greater plans, made with things a of squirrely changes. in but know some

So get further first the will to later improvements year, come just everything should we in for our make we see quarter? straight sure in that Or trying perhaps the modeling standpoint? Thanks.

Robert Finizio

So to I'll The piece Dawn and pay Mitch. But in. things coverage cash increase would be the goals and insurance was turn more immediate and kicking over in price unfold meeting the card, it that an see high the the next deductible would the plans their co-pay during impact. year you

the continue expect it would to year. throughout So

anything add? to Mitch want Okay, you

Mitchell Krassan

would I would, really at look that when looking quarter-over-quarter. I at

one revenue. So quarter impact And first year, may the of a versus see we net of we quarter but insurance the decrease think from and see will XXXX the first be we of made significant with in XXXX that typically card. given you changes cost co-pay don't and this regard a

Robert Finizio

pretty positive. So

Douglas Tsao

Great, thank you.

Operator

Guggenheim from comes question next Our Flanders Dana with Partners.

Unidentified Analyst

Devin quick the new and regarding questions. for One Flanders. this ANNOVERA is two had Hi, TBM was Dana just IMVEXXY. I've position on for preferred [ph]

year. it's got in to January. Just XX% back gains But I early guess share tracking. the know about it you wondering in that to how are XX% guys I gains share

still up. that additional you tailwind to I if be into seeing expect follow And XXXX. have So a just

Robert Finizio

pace. to we so it far as that. we absolutely it's early are Yes, over a the Dawn. turn I'll to in had But showed slides. I do. we track

So cash when raised to $XX we from the pay $XX.

in kind of growth we've to January. off growth of said then sooner as through three at and or stopped end expected weeks JPM at We we we about off a two fall of to returned to back March than thought. And back February, return that fall the to kind

is trending that well. So

We throughout about year We for accelerate expect good feel with the that sure. to that. that contract

Dawn Halkuff

some see Yes. we in it's And to and quarter is much we're the of second early what is especially Devin. an PBM. Rob that expect because the that that said, the forward. as add to of we're only confident from of [ph] that Rob or change, co-pay said, gauge as at as But would given with Hi, coverage within IMVEXXY the thing not some seeing impact of preferred

Unidentified Analyst

said. Well

at Okay, great, one a additional know of generic of the latter launch I new new I there's guess, know, one. I thank generic you. And XXXX. recent there's had just also And more I lane. half launch NuvaRing of a been,

Just seeing how XXXX? is you ANNOVERA for in guys impact kind expect that of which to

Robert Finizio

NuvaRing. if Slide Yes, the just you so know, NuvaRing, aren't the scripts that thirds you coming two if impact. from can XX% see you of positions, go coming actual see XX%, the seeing as we're the on about are XX, from And not you to patient, so

lasts implants, A for for a same very, Colon full mentioned screening. that's ANNOVERA removes acting to was procedure procedure cancer what that know, want aspect You a long NuvaRing a the the of the with product procedure. very that year for that like couldn't or and was have was lot a Dawn be developed not we're free, women been or X.X, Cologuard, right, didn't what that it and the something for population council IUDs data. ANNOVERA need the IUDs removed well. Well, And seeing worked does implants. thing they it And in wanted

Because contribution women the supply all And this in doctors long it void grow. impressed our out shrink, web market, with that's that currently see we're a need, think we which be. finding where comes by the that is the come I traffic are from previous free, of NuvaRing see the truly revenue not web I what think or and it we're you'll positioning other we've we there NuvaRing procedure pop way sources been interest developed counsel market much acting as continue you'll way avoid filling. contribution grow, the users to the the So see overall as that is to to and that

I a to So impact ring all. There answer of trajectory always NuvaRing is your users. is going to to at be subset supply question think going ANNOVERA don't of

probably run, long overall their whether share. to ultimate XX% or the in that of looking market our you're market share have at We the XX%

users numbers these and NuvaRing up go expect we down, to track to So not them. continue of we'll

Unidentified Analyst

you Great. Thank much. very

Robert Finizio

got Thanks You questions. it. for

Operator

not I'm the time. at showing I further for any turn the any remarks. closing And questions to call Rob back

Robert Finizio

how Thank I'm positioned excited covenants the call balance with really the revenue the you, sheet. that the joining future new for for everybody strengthen about we're today.

progressing. progress, the vitaCare and situation Our moving forward

you see quarter interest. thank for you all next you and So all. thank We'll your

Operator

that Ladies today's presentation. and concludes gentlemen,

disconnect wonderful may and You day. now have a

TherapeuticsMD (TXMD) 2 Mar 212020 Q4 Earnings call transcript